Related Experiment Videos
HPV vaccine MedImmune/GlaxoSmithKline.
1Novartis Research Institute, PO Box 80, Brunner Strasse 59, 1235 Vienna, Austria. andreas.billich@pharma.novartis.com
Current Opinion in Investigational Drugs (London, England : 2000)
|April 3, 2003
Summary
MedImmune and GlaxoSmithKline are developing a human papillomavirus (HPV) vaccine using virus-like particles. This multivalent vaccine, MEDI-517, targets HPV-16 and HPV-18 to prevent cervical cancer and genital tract infections.
Area of Science:
- Vaccinology
- Virology
- Oncology
Background:
- Human papillomavirus (HPV) infection is a major cause of cervical cancer.
- Current prevention strategies focus on prophylactic vaccines targeting high-risk HPV types.
Purpose of the Study:
- To develop and evaluate a novel multivalent vaccine (MEDI-517) for the prevention of HPV infection and associated cervical cancer.
- To assess the safety and immunogenicity of virus-like particle (VLP)-based HPV vaccine candidates.
Main Methods:
- Development of self-assembling, virus-like particles (VLPs) displaying HPV antigens.
- Combination of HPV-16 and HPV-18 VLP vaccine components into a multivalent formulation (MEDI-517) after Phase I studies.
- Initiation of Phase II clinical trials to evaluate MEDI-517 efficacy and safety.
Main Results:
- Phase I studies demonstrated the feasibility of VLP-based vaccine candidates (MEDI-501, MEDI-503, MEDI-504).
- MEDI-517, combining HPV-16 and HPV-18 components, advanced to Phase II trials.
- Ongoing Phase II trials are evaluating the multivalent vaccine's performance.
Conclusions:
- Virus-like particle technology offers a promising platform for developing effective HPV vaccines.
- MEDI-517 represents a potential advancement in the prevention of HPV-related diseases, including cervical cancer.
- Further clinical evaluation is necessary to confirm the vaccine's long-term efficacy and safety profile.